Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Tirzepatide treatment was associated with reduced body weight and diabetes risk across 3 years among individuals with obesity ...

If you’re starting a weight loss journey, you might have stumbled upon tirzepatide — the drug approved by the FDA (U.S. Food ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

Eli Lilly seeks to defend its interests in a lawsuit challenging the FDA's decision on the supply status of its drugs ...

The MHRA warns against buying weight-loss medicines illegally, emphasizing health risks and the need for prescriptions from ...

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

If you’re starting a weight loss journey, you might have stumbled upon tirzepatide — the drug approved by the FDA (U.S. Food and Drug Administration) under the brand names Mounjaro and Zepbound.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...

Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...